BridgeBio Pharma to Participate in February and March Investor Events
PALO ALTO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq:BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:
Related news for (BBIO)
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
- BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
- bridgebio pharma reports topline results from phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (cah)
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)